Kornimate/medical-research-clean huggingface dataset:
permanent observatory of heart failure

Conditions: Acute Heart Failure

Summary: the observatory consists of a row of data collection on a population composed of all patients with heart failure cared for in centers participating in the national education program for patients (named i-care) in the form of two groups. patients who are undergoing a program of therapeutic education track are listed and included in the group of patients educated. patients who receive no education or only a minimal element for any reason whatsoever are also listed and included in the group of patients who are not educated. the following of patients will be periodic after their entry in the observatory, up to 2 years of follow up.

the center for patients with heart failure cared for in a center practicing therapeutic education dedicated to heart failure. the definition of heart failure selected for inclusion is that recommended by the european society of cardiology : presence of at least two signs or symptoms of heart failure (dyspnea, edema of the ankles crackles) at rest or during exercise associated with objective evidence (preferably by echocardiography) of cardiac dysfunction ( systolic and / or diastolic) (resting) and in case of doubt, a response to specific treatment of heart failure. all patients who are undergoing a program of therapeutic education track are listed and included in the group of patients educated. all patients who receive no education or only a minimal element for any reason whatsoever are also listed and included in the group of patients who are not educated. follow up is done by cras at the french society of cardiology, by mailing and phone contacts.

Eligibility criteria:
inclusion criteria: * patient with heart failure * patient supported by a center participating in the i-care french program exclusion criteria: * refusal by the patient to be listed in an observatory

Keywords: therapeutic education
a study of ly3454738 in the treatment of adult participants with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the main purpose of this study is to describe the efficacy and safety of ly3454738 in adult participants with moderate-to-severe atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: * are candidates for systemic therapy. isa specific: * have moderate-to-severe ad, defined as meeting all of the following criteria, at the first dosing visit: * easi score greater than or equal to (≥)16 * viga-ad score ≥3, and * ≥10% of bsa involvement (per easi bsa). * have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this isa and agree to daily use of at least 1 emollient continuously throughout the study. exclusion criteria: isa specific: * have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master immb. * are currently being treated with topical or systemic therapy * recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.
macrophages, portal hypertension, and liver function during abbvie treatment of chronic hepatitis c

Conditions: Hepatitis C

Summary: investigation of the effects of the new abbvie direct acting anti-viral (daa) treatment of chronic viral hepatitis c infection on the macrophage specific activation marker soluble cd163, portal hypertension determined by the hepatic venous pressure gradient (hvpg), and metabolic liver function determined by the galactose elimination capacity (gec) test and the functional hepatic nitrogen clearance (fhnc).


Eligibility criteria:
inclusion criteria: * chronic hepatitis c genotype 1 or 4 patients initiating the new abbvie treatment (paritaprevir, ritonavir, ombitasvir og dasabuvir sammen med ribavirin) * child-pugh a liver cirrhosis exclusion criteria: * severe liver dysfunction - child-pugh klasse b-c * life expectancy less than 6 months * planned liver transplantation or tips procedure within 6 months * non-compliance to treatment or study procedures * allergy to the daa drugs used (paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin) * pregnancy or expected pregnancy during the study (anti-conception has to be used) * breast feeding * portal vein thrombosis * liver cancer or other malignancies * alcohol consumption

Keywords: direct acting antiviral treatment scd163 portal hypertension metabolic liver function cirrhosis
korea transradial coronary intervention prospective registry (kotri)

Conditions: Coronary Artery Disease

Summary: the aim of this registry is to analyze several factors affecting the procedural success and clinical outcomes at 1 year of follow-up according to the approach site.

this registry is a multi-center prospective registry for patients undergoing coronary angiography or percutaneous coronary intervention either transradial or transfemoral approach from 22 centers in south korea. the aim of this registry is to analyze several factors affecting the procedural success and clinical outcomes at 1 year of follow-up according to the approach site.

Eligibility criteria:
inclusion criteria: * all consecutive hospitalized patients undergoing coronary angiography or percutaneous coronary intervention exclusion criteria: * no exclusion criteria

Keywords: coronary artery disease
fibrinogen early in severe trauma study junior

Conditions: Trauma; Hemorrhage; Coagulopathy; Pediatrics

Summary: 1. haemorrhage in severe trauma is a significant cause of mortality and is potentially the most preventable cause of death in paediatric trauma patients 2. trauma induced coagulopathy (tic) is a complex coagulopathy associated with severe trauma 3. hypo/dysfibrinogenaemia plays an important role in tic 4. early replacement of fibrinogen may improve outcomes 5. fibrinogen replacement is potentially inadequate in standard fixed ratio major haemorrhage protocols (mhp) utilising plasma and/or cryoprecipitate 6. the majority of centres utilise cryoprecipitate for additional fibrinogen supplementation as part of a mhp 7. cryoprecipitate administration is often delayed (between 60 - 120 minutes) in a fixed ratio mhp 8. it is clear early intervention in severe traumatic haemorrhage is associated with improved outcomes - crash 2 and proppr studies 9. increasing interest in the use of fibrinogen concentrate (fc) in severe bleeding but not supported by high level evidence 10. benefits of fc - viral inactivation, known dose, easily reconstituted, can be administered quickly in high dose and stored at room temperature in the trauma resuscitation bay 12. no previous studies comparing fc and cryoprecipitate in bleeding paediatric trauma patients 13. fibrinogen supplementation will be guided by an accepted rotem targeted treatment algorithm 14. pilot, multi-centre randomised controlled trial comparing fc to cryoprecipitate (current standard practise in fibrinogen supplementation) 15. hypothesis: fibrinogen replacement in severe traumatic haemorrhage can be achieved quicker with a more predictable dose response using fibrinogen concentrate compared to cryoprecipitate 16. it is imperative that robust and clinically relevant trials are performed to investigate fibrinogen supplementation in paediatric trauma patients before widespread adoption makes performing such studies unfeasible


Eligibility criteria:
inclusion criteria: 1. child affected by trauma (3 months to 18 years) 2. judged to have significant haemorrhage or predicted to require significant transfusion by the treating clinician 3. activation of local mhp or transfusion of emergency red blood cells (pre-hospital or at trauma centre) exclusion criteria: 1. injury judged incompatible with survival 2. randomisation unable to occur within 6 hours of hospital admission 3. pregnancy 4. known personal or parental objection to blood products 5. known coagulation disorder (i.e. haemophilia, von willebrand disease) 6. previous dedicated fibrinogen replacement this admission 7. pre-trauma centre dedicated fibrinogen replacement 8. participation in competing study

Keywords: fibrinogen concentrate cryoprecipitate
the dpp-4 inhibitor vildagliptin as adjunct in major depressive disorder patients

Conditions: Major Depressive Disorder

Summary: vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (dpp-4), increases glucagon-like peptide-1 (glp-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk. a retrospective longitudinal study by rizzo et al. showed that dpp-4 inhibitors administration could have protective effects against cognitive decline in diabetic elderly. is has been observed that glp-1 affects brain metabolism, increases neuritic growth, and protects neuronal cells from oxidative stress and death.


Eligibility criteria:
inclusion criteria: * eighty adult outpatients with the diagnostic and statistical manual of mental disorders-iv (dsm-iv) diagnosis of mdd based on a mini neuropsychiatric interview (mini) (american psychiatric association., 2000; sheehan et al., 1998), without psychotic features and a total 17 item ham-d score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (hamilton, 1960). * patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study. exclusion criteria: * patients with bipolar i or bipolar ii disorder * patients with personality disorders * patients with eating disorders * patients with substance dependence or abuse * patients with concurrent active medical condition * patients with history of seizures * patients with history of receiving electroconvulsive therapy (ect) * patients with inflammatory disorders * patients with allergy or contraindications to the used medications * patients with finally pregnant or lactating females * cardiovascular disorders * severe renal impairment: creatinine clearance of ≤ 25 ml/min * moderate or severe hepatic impairment
effect of sipjeondaebo-tang for cancer related anorexia in cancer patients

Conditions: Cancer-related Problem/Condition

Summary: to determine efficacy and safety of sipjeondaebo-tang for cancer patients suffering from anorexia after chemotherapy. sipjeondaebo-tang will be administered for 4 weeks, 3 times per day after a meal. changes of faact scale, anorexia vas, weight, bmi, clinical laboratory test such as acth, cortisol, chrelin, il-6, esr, crp will be measured and analyzed.


Eligibility criteria:
inclusion criteria: * men and women ages 20 to 80 years * individuals who are suffering from cancer-associated anorexia * patients within 1 month after completion of chemotherapy * no plan for additional chemotherapy or radiotherapy * anorexia visual analogue scale (vas) ≥ 40/100mm * qi deficiency scale ≥ 30 or blood deficiency scale ≥ 30 * neutrophil ≥ 1,500/㎕, platelet ≥ 100,000/㎕ * total bilirubin lower than upper limit of normal (1.2 mg/㎗) * alt, ast lower than 2-fold the upper limit of normal * creatinine lower than 1.5 fold the upper limit of normal(1.09 mg/㎗) * written informed consent for participation in the trial exclusion criteria: * patient impossible to oral intake * patient 5 years after cancer diagnosis * ecog performance status score \> 3 * patient with dementia, delirium, depression * patient who complain of more than 7 points when we use numeric rating scale, which can affect appetite or calorie intake, within 2 weeks of screening * patient with diseases which can influence on appetite (such as hypoadrenalism, etc) * patient who are taking appetizers (such as megestrol acetate, corticosteroids, thalidomide) * women who has possibility of a pregnancy * others who are judged not to be appropriate to study
comparison of vibrating mesh nebulizer versus jet nebulizer in the pediatric asthma patient

Conditions: Asthma

Summary: the purpose of this study is to compare clinical outcomes related to the current practice of using a jet nebulizer (jn) with aerosol mask (am) or mouthpiece (mp) versus a vibrating mesh nebulizer (vmn) with a valved-mask (vm) or mp in the treatment of acute moderate to severe asthma in children's medical center dallas emergency department (cmced).

the purpose of this study is to compare clinical outcomes related to the current practice of using a jet nebulizer (jn) with aerosol mask (am) or mouthpiece (mp) versus a vibrating mesh nebulizer (vmn) with a valved-mask (vm) or mp in the treatment of acute moderate to severe asthma in children's medical center dallas emergency department (cmced). the investigators hypothesize that using the combination of a vmn and vm or mp will result in fewer hospital admissions and decrease length of stay in cmced when compared to the current practice of using a jn and am or mp.

Eligibility criteria:
inclusion criteria: 2 to 18 year old (up to 19th birthday) otherwise healthy children with primary diagnosis of acute moderate to severe exacerbation of asthma presenting to children's medical center emergency department, dallas - exclusion criteria: * children \< 2 years old * children with comorbid/complex medical conditions such as: congenital or acquired cardiovascular disease, cystic fibrosis, chronic lung disease (other than asthma), bronchopulmonary dysplasia, airway anomalies (e.g., tracheomalacia) or immunodeficiency syndromes. * patients with coexisting medical condition such as pneumonia * patients in impending respiratory failure as determined by treating physician * patients that have had oral corticosteroids within 24hrs of cmced admission * patients that have had bronchodilator treatment within one hour of cmced admission
d2 versus d1 gastrectomy of operable gastric cancer

Conditions: Gastric Cancer

Summary: surgery is the mainstay treatment of operable gastric carcinoma but the optimal extent of lymph node (ln) dissection is controversial. the aim of this observational study is to assess the outcomes after curative d2 compared to d1 gastrectomy of operable gastric carcinoma regarding operative and long term oncological outcomes.

this observational study included 80 consecutive patients presented by operable gastric cancer treated by d2 gastrectomy at alexandria university hospital between january 2010 and january 2016, (group i). another 68 consecutive patients presented by operable gastric cancer treated by d1 gastrectomy earlier during the same period were included as a control (group ii). all patients had undergone preoperative gastroscopy and biopsy, chest and abdomen computed tomography (ct). all surgeries were performed by surgeons experienced in both d1 and d2 dissection and a standardized protocol for d1 and d2 gastrectomy was followed in all patients. the type of gastrectomy (distal or total) was done according to the site of the tumor; distal gastrectomy was done if there is a free safety margin of 4 cm beyond the proximal resection line otherwise total gastrectomy was done. resection of the spleen and/or pancreatic tail were done if directly invaded by the primary tumor or metastatic ln. patients with p t2 or greater, or with positive ln received adjuvant chemotherapy. follow up was done as outpatient visits for average 5 years. both groups were compared regarding postoperative morbidity and mortality, disease recurrence and survival rates.

Eligibility criteria:
inclusion criteria: * patients younger than 80 years with a histologically confirmed operable adenocarcinoma of the stomach with complete follow up after surgery for average 5 years exclusion criteria: * complicated gastric cancer (obstructed or perforated) * irresectable or metastatic disease * previous or coexisting cancer * prior gastric surgery.

Keywords: operable gastric cancer d2 gastrectomy d1 gastrectomy operative mortality & morbidity oncological outcomes
the impact of renin-angiotensin system on brain activation during hypoglycaemia in healthy men, a pet study

Conditions: Hypoglycemia; Cognitive Impairment

Summary: the purpose of this study is to evaluate the cerebral blood flow in subjects with high and low activity in the renin-angiotensin system (ras).the renin-angiotensin system is a hormone system which is involved in the regulation of the blood pressure. earlier studies have shown that high ras activity is associated with a more pronounced cognitive impairment during hypoglycaemia compared to low ras activity in both type 1 diabetic patients and healthy volunteers. we intend to examine brain activity by oxygen-15 labelled water-pet scanning during hypoglycaemia in response to cognitive function testing in 20 healthy male volunteers with high and low ras activity, respectively

the purpose of this study is to evaluate the regional cerebral blood flow in subjects with high and low activity in the renin-angiotensin system (ras). earlier studies have shown that high ras activity is associated with a more pronounced cognitive impairment during hypoglycaemia compared to low ras activity in both type 1 diabetic patients and healthy volunteers. we intend to examine brain activity by oxygen-15 labelled water-pet scanning during hypoglycaemia in response to cognitive function testing in 20 healthy male volunteers with high and low ras activity, respectively.

Eligibility criteria:
inclusion criteria:male age 18-40 years right-handed in good general health based on history high/low ras activity (high ace activity, a-allele for angiotensin ii receptor (subtype 2) and high plasma angiotensinogen, or low ace activity, low plasma angiotensinogen and not carrier of the a-allele for angiotensin ii receptor (subtype 2)). - exclusion criteria: any evidence of mental, neurological or medical illnesses. the presence of ferromagnetic metal in the body. claustrophobia exposure to radiation within the last year -

Keywords: hypoglycemia cognitive impairment pet calcap
study to demonstrate the efficacy and safety of propranolol oral solution in infants with proliferating infantile hemangiomas requiring systemic therapy

Conditions: Infantile Hemangioma

Summary: there is an unsatisfied medical need for a first-line treatment of proliferating ihs with a good benefit/risk profile. based on the recent findings of encouraging results obtained with propranolol in a series of infants with severe infantile hemangioma (ih), propranolol is expected to be of significant benefit in the management of the condition. the present study has been designed to confirm efficacy of propranolol in severe ih by demonstrating superiority over placebo and to document the safety profile of propranolol in this indication.

primary objective the primary objective of this study is to identify the appropriate dose and duration of propranolol treatment and demonstrate its superiority over placebo based on the complete/nearly complete resolution of target ih at w24.

Eligibility criteria:
inclusion criteria: * proliferating ih (target hemangioma) requiring systemic therapy anywhere on the body except on the diaper area with largest diameter of at least 1.5 cm exclusion criteria: - the patient presents with one or more of the following medical conditions: congenital hemangioma; kasabach-merritt syndrome; bronchial asthma; bronchospasm; hypoglycaemia (\< 40 mg/dl or at risk); untreated phaeochromocytoma; hypotension (\< 50/30 mmhg); second or third degree heart block; cardiogenic shock; metabolic acidosis; bradycardia (\< 80 bpm); severe peripheral arterial circulatory disturbances; raynaud's phenomenon; sick sinus syndrome; uncontrolled heart failure or prinzmetal's angina; documented phaces syndrome with central nervous system involvement * the patient has previously been treated for ih, including any surgical and/or medical procedures (e.g. laser therapy) * the patient is known to have a hypersensitivity to propranolol and/or any other beta-blockers * one or more of the following types of ih are present: * life-threatening ih * function-threatening ih (e.g. those causing impairment of vision, respiratory compromise caused by airway lesions, etc.) * ulcerated ih (whatever the localisation) with pain and lack of response to simple wound care measures * the patient was born prematurely and has not yet reached his/her term equivalent age (e.g. an infant born 2 months prematurely cannot be included before the age of 2 months) * lvef (left ventricular systolic function) ≤40% and/or cardiomyopathy and/or hereditary arrhythmia disorder

Keywords: infantile hemangioma propranolol
establishment of nafld cohort and development of fibrosis markers

Conditions: Fibrosis of Liver

Summary: this study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.

* acoustic radiation force impulse elastography and transient elastography * liver tissue (frozen tissue, paraffin block) * whole blood, serum * fat amount ratio ct (visceral adipose tissue, subcutaneous adipose tissue amount) * body composition analyzer (inbody scale):total fat/muscle mass and appendicular skeletal muscle mass * pulmonary function test with post-bronchodilator response and dlco * ekg, echocg, heart ct (coronary calcium score), and pusle wave velocity (ai index, arterial stiffness) * brain mri or ct * upper esophagogastroscopy and colonoscopy * berlin score questionnaire and polysomnography

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed fatty liver disease * patients with radiologically confirmed fatty liver disease exclusion criteria: * history of significant alcohol consumption * viral hepatitis * autoimmune hepatitis * metabolic diseases (e.g. hemochromatosis, m. wilson, alpha 1-antitrypsin deficiency) * hepatotoxic medication (e.g. amiodarone)

Keywords: fibrosis markers
fluorescent cholangiography and bile duct stones

Conditions: Gall Stones, Common Bile Duct

Summary: background. x-ray cholangiography has a high sensitivity and specificity of detecting bile duct stones and is the gold standard. there are no studies describing the sensitivity and specificity of ifc for bile duct stone detection. research question. what is the sensitivity of ifc to visualize bile duct stones? method. prospective study with 40 patients undergoing planned laparoscopic cholecystectomy with preoperative magnetic resonance cholangiopancreatography (mrcp) (gold standard) and intraoperative ifc, x-ray cholangiography and choledochuscopy in that order. primary outcome. sensitivity of visualization of bile duct stone by fluorescent cholangiography and secondary outcome is visualization of anatomy.


Eligibility criteria:
inclusion criteria * patients suspected of having bile duct stones by either blood samples, mrcp or medical history (see definitions) * patient age ≥ 18 years * preoperative mrcp * operation performed by a project surgeon exclusion criteria * open cholecystectomy (including conversion from laparoscopic to open) * acute cholecytitis or cholangitis * pancreatitis * iodine or indocyanine green allergy * liver or renal insufficiency * thyrotoxicosis * cholecystectomy not the primary surgical procedure * pregnancy or lactation * legally incompetent for any reason * withdrawal of inclusion consent at any time

Keywords: fluorescence cholangiography cholecystectomy, laparoscopic